FDA Authorizes Johnson Single Shot Vaccine

Johnson & Johnson today [Feb 27] announced that the U.S. Food and Drug Administration [FDA] has issued Emergency Use Authorization for its single-dose Covid-19 vaccine.

“This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination,” the company said.

“This milestone follows a year of incredible work by our dedicated teams and unprecedented collaboration with health leaders around the world – all of whom shared a goal of bringing a single-shot vaccine to the public,” said Alex Gorsky, Chairman and Chief Executive Officer at Johnson & Johnson. “We will do everything we can to help bring this pandemic to an end, in the United States and throughout the world.”

The Johnson & Johnson vaccine differs from the other vaccines which have already been approved in that it is a single dose, versus two doses.

Bermuda, which is ranked in the top 10% of all nations worldwide as far as vaccinations per capita, is using the Pfizerv vaccine, which is being supplied to Bermuda and the other Overseas Territories by the UK.

As the island and world deals with the Covid-19 pandemic, we are doing our best to provide timely and accurate information, and you can find more information on the links below.

• All: Our coverage of the Covid-19 pandemic here
• Official: The Bermuda Government website here
• World Stats: Live graph of all cases worldwide here
• Bermuda Stats: Chart of the Bermuda stats here
• Timeline: Visual look at the timeline here
• Comprehensive: Our BermudaCovid.com website here
• Live Updates: Continuous updates of the latest news here.

#Covid19 #CovidVaccine #WorldNews

Category: All